The Chan Zuckerberg Initiative announced Thursday the launch of rBio, the first artificial intelligence model trained to reason about cellular biology using virtual simulations rather than requiring expensive laboratory experiments — a breakthrough that could dramatically accelerate biomedical research and drug discovery.
The reasoning model, detailed in a research paper published on bioRxiv, demonstrates a novel approach called "soft verification" that uses predictions from virtual cell models as training signals instead of relying solely on experimental data. This paradigm shift could help researchers test biological hypotheses computationally before committing time and resources to costly laboratory work.
"The idea is that you have these super powerful models of cells, and you can use them to simulate outcomes rather than testing them experimentally in the lab," said Ana-Maria Istrate, senior research scientist at CZI and lead author of the research, in an interview. "The paradigm so far has been that 90% of the work in biology is tested experimentally in a lab, while 10% is computational. With virtual cell models, we want to flip that paradigm."
The announcement represents a significant milestone for CZI's ambitious goal to "cure, prevent, and manage all disease by the end of this century." Under the leadership of pediatrician Priscilla Chan and Meta CEO Mark Zuckerberg, the $6 billion philanthropic initiative has increasingly focused its resources on the intersection of artificial intelligence and biology.
